Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 4/20 | 0.37 |
| ▸ | TEC | P42680 | 3/20 | 0.35 |
| ▸ | TXK | P42681 | 3/20 | 0.35 |
| ▸ | BMX | P51813 | 3/20 | 0.35 |
| ▸ | BTK | Q06187 | 3/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 6/20 | 0.35 |
| ▸ | RAB9A | P51151 | 6/20 | 0.35 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MITF | O75030 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7132134 | 0.83 | F10 (0.44) | ABCB1RXFP1ABCC1F10 | |
| SCHEMBL5530794 | 0.78 | F10 (0.56) | F10 | |
| SCHEMBL5532013 | 0.76 | MEN1 (0.38) | RXFP1NPC1RAB9AGAATP53 | |
| SCHEMBL5530380 | 0.75 | F10 (0.47) | ABCB1ABCC1F10 | |
| SCHEMBL5532509 | 0.75 | F10 (0.47) | ABCB1ABCC1F10 | |
| SCHEMBL5541061 | 0.74 | F10 (0.46) | ABCB1ABCC1F10 | |
| SCHEMBL5531799 | 0.74 | F10 (0.46) | ABCB1ABCC1F10 | |
| SCHEMBL5534413 | 0.72 | F10 (0.37) | RXFP1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL5534115 | 0.72 | NPC1 (0.36) | NPC1RAB9AGAAMITFTP53 | |
| SCHEMBL5550016 | 0.72 | NPC1 (0.41) | RXFP1NPC1RAB9ATP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312235-B2 | Benzamide inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | claimed |
| EP-1373194-B1 | BENZAMIDE INHIBITORS OF FACTOR Xa | MILLENNIUM PHARM INC (US) | 2007-08-01 | — | — | EP | claimed |
| EP-1373194-A1 | BENZAMIDE INHIBITORS OF FACTOR Xa | Millennium Pharmaceuticals, Inc. (US) | 2004-01-02 | — | — | EP | claimed |
| WO-2002079145-A1 | BENZAMIDE INHIBITORS OF FACTOR Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-10-10 | — | — | WO | claimed |
| US-7312235-B2 | Benzamide inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1373194-A1 | BENZAMIDE INHIBITORS OF FACTOR Xa | Millennium Pharmaceuticals, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030069250-A1 | Benzamide inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2002079145-A1 | BENZAMIDE INHIBITORS OF FACTOR Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069250-A1 | Benzamide inhibitors of factor Xa | SERPINC1, TFPI, F12 | ABCB1 2633/4885TEC 2328/4885TXK 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.